KRAS and colorectal carcinoma: We then show that this further overexpression of PRMT5 in the KRAS mutant CRC cells results in more substantial growth inhibition, apoptosis, and cell cycle arrest following PRMT5 inhibitor treatment when compared to the KRAS WT CRC cells.